上海药明巨诺生物科技有限公司 JW Therapeutics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma 2022-02-27 18:30
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building 2022-01-10 09:30
JW Therapeutics Presents Primary Clinical Response on Carteyva(R) (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting 2021-12-15 10:37
JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129 2021-09-27 20:00
JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) 2021-09-26 20:00
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China 2021-09-06 19:03
JW Therapeutics Announces Strategic Partnership with MediTrust Health 2021-08-20 17:00
JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses With Eureka Therapeutics' Solid Tumor Technologies in China 2020-07-20 21:33
1 2